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Norway
α2-adrenoceptors (α2AR) lower central sympathetic output and peripheral catecholamine
release, and may therefore prevent sympathetic hyperactivity and hypertension. The
α2AR are dysfunctional in male spontaneously hypertensive rats (SHR). Premenopausal
females are less hypertensive than males. The purpose of this study was to test if
this difference could be explained by functional α2AR in the female SHR. A 15-min
tyramine-infusion was used to stimulate norepinephrine release through the re-uptake
transporter, consequently preventing re-uptake. Presynaptic control of vesicular release
will therefore be reflected as differences in overflow to plasma. The surgical trauma
activates secretion of epinephrine, also subjected to α2AR auto-inhibition. Blood
pressure was monitored through a femoral artery catheter and cardiac output by
ascending aorta flow in 12-14 weeks-old (early hypertension) SHR and normotensive
rats (WKY). Total peripheral vascular resistance (TPR) was calculated. Female SHR,
unlike male, were close to normotensive. Pre-treatment with none-selective (clonidine) or
non-A-selective (ST-91) α2AR agonist reduced, and none-selective α2AR antagonist (L-
659,066) increased tyramine-induced norepinephrine overflow in female WKY and SHR.
L-659,066 also increased secretion of epinephrine. The L-659,066-induced increase in
catecholamine release was further enhanced by additional pre-treatment with ST-91 or
angiotensin AT1 receptor antagonist (losartan) in SHR only. L-659,066 eliminated the
tyramine-induced rise in TPR in both strains in female rats. Conclusion: α2AR-mediated
control of catecholamine release and vascular tension was therefore functional in female
SHR, unlike that previously observed in male SHR. Functional α2AR is likely to have a
protective function and may explain the lack of hypertension in the young female SHR.
Keywords: α2-adrenoceptors, angiotensin AT1 receptor, sympathetic nervous system, norepinephrine,
epinephrine, female rats, spontaneously hypertensive rats, total peripheral vascular resistance
INTRODUCTION
Premenopausal women are less hypertensive thanmales of the same age (Lerner and Kannel, 1986).
The same is true in spontaneously hypertensive rats (SHR; Maris et al., 2005). The antihypertensive
mechanisms involved are not known (Reckelhoff and Fortepiani, 2004), but a difference in
sympathetic activity has been suggested, since the sympathetic tone will increase with age
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(Ng et al., 1993; Seals and Esler, 2000). The release of
catecholamines from sympathetic nerves (Figure 1) and the
adrenal glands is inhibited by α2-adrenoceptors (AR), and
α2AR in vascular smooth muscle cells (VSMC) promote
vasoconstriction. These functions were failing in male SHR
(Remie et al., 1992; Zugck et al., 2003; Berg and Jensen, 2013),
and the dysfunctional auto-inhibition of catecholamine release
may be a contributory factor in the development of high blood
pressure (BP). This conclusion was compatible with the high
levels of circulating catecholamines and hypertension observed
in α2AAR-knock-out mice (Makaritsis et al., 1999). In female
rats, α2AR antagonist enhanced the release of norepinephrine
in response to sympathetic nerve stimulation with a greater
effect than in male rats in the isolated heart (Du et al., 1991),
although not in the tail artery (Garcia-Villalon et al., 1997).
These observations may suggest a gender-related difference in
α2AR-mediated inhibition of release.
The α2AR comprise three subtypes, i.e., A, B, and C. The
α2A and α2C are the main subtypes involved in auto-inhibition
of catecholamine release, whereas the α2B-subtypemayinduce
VSMC contraction (Link et al., 1996; Hein et al., 1999;
Trendelenburg et al., 2003a; Berg et al., 2012). The failing α2AR-
mediated inhibition of release in SHR was restored by enhanced
α2CAR signaling, achieved either directly by α2CAR agonist, or
indirectly by angiotensin AT1 receptor (AT1R) antagonist (Berg,
FIGURE 1 | Presynaptic modulation of vesicular norepinephrine release
studied by the use of tyramine. Tyramine stimulates the release of
norepinephrine by reversed transport through the norepinephrine re-uptake
transporter (NET). The regular re-up-take of norepinephrine through NET will
therefore be prevented, resulting in an elevated overflow to plasma. The
released norepinephrine and other agonists present will activate the
presynaptic receptors and influence the amount released from synaptic
vesicles and, hence, the overflow of norepinephrine (NE) to plasma.
Differences in the plasma norepinephrine concentration will therefore reflect
changes in release induced by presynaptic receptor agonist or antagonist.
Stimulation of the α2CAR-subtype may enhance α2AAR-subtype-mediated
inhibition of release, possibly because the α2Aα2CAR heterodimer is more
resistant to G-protein coupled receptor kinase (GRK)-desentization than the
α2Aα2AAR or α2Cα2CAR homodimers. The angiotensin AT1 receptor (AT1R)
may stimulate release by inhibiting down-stream signaling of the α2CAR.
However, α2CAR may also inhibit renal renin release, and through that reduce
presynaptic AT1R counter-action of α2 AR auto-inhibition of release.
Gq,G-protein of the q subtype; Gi,inhibitory G-protein.
2013). The latter may be explained by that angiotensin II, through
the AT1R, stimulated release by interfering with inhibitory G
(Gi)-protein signaling (Figure 1), an interaction which involved
the α2C-subtype only (Trendelenburg et al., 2003b). Since the
renin-angiotensin system has been implicated in postmenopausal
hypertension (Reckelhoff and Fortepiani, 2004), the impact of
α2CAR and AT1R on α2AR function may be different in male and
female SHR.
The present study therefore analyzed if there was a gender-
related difference in α2AR auto-inhibition of catecholamine
release and/or control of vascular tension which may explain
the lower BP in the female SHR. α2AR functionality was
studied by the effect of the non-selective α2AR antagonist
L-659,066 on tyramine-stimulated norepinephrine release.
Tyramine stimulates norepinephrine release by reversing the
transport through the norepinephrine re-uptake transporter
(NET), consequently blocking re-uptake (Figure 1). Activation
of the presynaptic receptors by the released norepinephrine
and/or other agonists present will alter the vesicular release of
norepinephrine, and this will be reflected as differences in the
overflow of norepinephrine to plasma (Berg et al., 2012; Berg
and Jensen, 2013). Neither L-659,066, nor tyramine, crosses the
blood-brain barrier (Oldendorf, 1971; Clineschmidt et al., 1988).
The tyramine-induced release of norepinephrine is therefore
not directly dependent on the sympathetic tone, which will
be influenced by factors such anesthesia, ventilation and rat
strain, but activated pharmacologically in the nerve terminal.
Tyramine also allowed a simultaneous study of the role of
α2AR in the cardiovascular response to norepinephrine release.
Furthermore, as established in male rats, the trauma induced by
the surgical procedure activated some secretion of epinephrine,
also subjected to receptor-mediated release control (Berg et al.,
2012; Berg and Jensen, 2013).
MATERIALS AND METHODS
Experimental Procedure
All experiments were approved by The Norwegian Animal
Research Authority (NARA) and conducted in accordance
with the Directive 2010/63/EU of the European Parliament.
Normotensive rats (Wistar Kyoto, WKY) and SHR (Okamoto,
SHR/NHsd strain) were bred in-house, and the female rats
included in this study were from the same litters as male
rats included here and in previous publications. The rats used
in the experimental protocols below were 12–14 weeks old,
representing the early hypertensive stage in male SHR. Forty-
nine female WKY (179 ± 2 g b.w.) and 8 male WKY (291± 9 g
b.w.), and 48 female SHR (178 ± 1 g b.w.) and 8 male SHR
(276 ± 13 g b.w.) were included. In addition, BP was recorded
in anesthetized, retired breeders (6–8 rats per group) from the
same stock (245 ± 8 and 391 ± 7 g b.w., 49 ± 1 and 45± 1
weeks, respectively, in female and male WKY, and 231 ± 7 and
401 ± 10 g b.w., 54 ± 3 and 47 ± 3 weeks, in female and male
SHR). The older rats were not subjected to further experiments.
The rats were housed on 12/12 h light/dark cycles, and allowed
food (conventional rat chow diet with 0.7% NaCl) and water ad
lib until the time of the experiment. The rats were anesthetized
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with pentobarbiturate (70–75mg/kg, i.p.) and tracheotomised.
Systolic (SBP) and diastolic (DBP) BP were monitored through
a catheter in the femoral artery, which also recorded heart
rate (HR) before the rats were connected to ventilator. After
thoracotomy, entering through the third intercostal space,
cardiac output (CO=minus cardiac flow) andHRwere recorded
by a flow probe on the ascending aorta, connected to a T206
Transonic Flow meter (Transonic Systems Inc., Ithaka NY,
USA). Mean arterial BP (MBP = SBP-DBP/3+DBP) and total
peripheral vascular resistance (TPR=MBP/CO)were calculated.
The rats were on a positive pressure ventilator throughout
the experiment, ventilated with air. Body temperature was
maintained at 37–38◦C by external heating, guided by a
thermo sensor inserted inguinally into the abdominal cavity.
All drugs were dissolved in PBS, and injected through a
catheter in the femoral vein (0.6–1.0ml/kg). When all surgery
was completed, the arterial catheter was flushed with 0.1ml
PBS (0.01M Na-phosphate, pH 7.4, 0.14M NaCl) containing
500 IU heparin/ml. The rats were then allowed to stabilize
for 10min.
Experimental Design
An overview of the experiments performed on the 12–14 weeks-
old rats is shown in Figure 2. All rats were infused with
tyramine (1.26 µmol/min/kg, 15min) to stimulate endogenous
norepinephrine release (Berg et al., 2012; Berg and Jensen,
2013). Control rats were pre-treated with PBS 10min before
tyramine. The experimental groups were pre-treated with the
α2AR-antagonist L-659,066 (4.4 µmol/kg, –10min) (Berg et al.,
2012; Berg and Jensen, 2013), with PBS followed 10min later by
α2(non−A)AR-agonist ST-91 (24 nmol/kg) (Berg, 2013), or with
L-659,066 followed by ST-91, allowing 15min between ST-91
and tyramine. These drugs do not cross the blood-brain barrier
(Oldendorf, 1971; Clineschmidt et al., 1988; Takano et al., 1992).
Rats were also pre-treated with the non-selective α2AR-agonist
clonidine (151 nmol/kg) (Berg and Jensen, 2013), which crosses
the blood-brain barrier, followed by tyramine 15min later. In
addition, rats were pre-treated with the AT1R antagonist losartan
(79 µmol/kg) (Berg, 2002), followed by PBS or L-659,066 10min
later. Six-8 rats were included in each group.
Measurement of Plasma Catecholamines
Blood was sampled from the arterial catheter after the
tyramine-observation period, but without discontinuing the
tyramine infusion. The blood (1.5ml) was collected into tubes
containing 40 µl 0.2M glutathione and 0.2mol/L ethylene
glycol-bis (2-aminoethylether)-N,N,N’,N’-tetraacetic acid
(EGTA) (4◦C). Plasma was stored at –80◦C until catecholamine
concentrations were determined using 400 µl plasma and the
5000. Reagent kit for HPLC analysis of Catecholamines in plasma
from Chromsystems GmbH, Munich, Germany, as described
by the manufacturer. The samples were run on a Shimadzu
monoamines analyzer (HPLC) system, using an isocratic flow
rate of 0.8ml/min, and an electrochemical detector (Decade
II) and a SenCell electrochemical flow cell (Antec Leyden,
Zoeterwoude, The Netherlands).
Drugs
L-659,066 was a kind gift from Merck, Sharp and Dohme Labs,
Rahway, NJ, USA. ST-91 was from TOCRIS bioscience, Bristol,
UK. The remaining drugs were from Sigma Chemical Co., St.
Louis, MO, USA.
Statistical Analyses
Results are presented as mean values ± s.e.mean. Data
were averaged every min in all experiments. For the narrow
peak-pressor response to ST-91, data were averaged every 5 s.
The cardiovascular response-curves to agonists and tyramine
were analyzed using Repeated Measures Analyses of Variance
and Covariance, first as over-all tests within each strain, and
subsequently for each group separately or between groups.
Significant responses were subsequently located at specific times
using one-sample Student’s t-tests, and were indicated in the
figures with an asterix within the group symbol. Differences
between groups at the same times were identified using
two-sample Student’s t-tests. For the TPR-response, these ad
hoc analyses were done for (1) the TPR-peak-response which
occurred after 3 or 4min, or at 4min when a TPR-peak was
not present, and (2) after 15min. For the HR-response, the
Student’s t-tests were performed only at 15min. The plasma
catecholamine concentrations were first analyzed using two-way
FIGURE 2 | An overview of the design of the experiments performed on 12–14 weeks-old rats. PBS, sham injection with vehicle; L-659,066, peripherally
restricted, non-selective α2AR-antagonist; Clonidine, not restricted, non-selective α2AR-agonist; ST-91, peripherally restricted α2(non−A)AR-agonist; Losartan, AT1R
antagonist; Tyramine, stimulates reverse transport of norepinephrine through the re-uptake transporter.
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ANOVA, and the cardiovascular baselines and the effect of
pre-treatment by one-way ANOVA. Group and strain-related
differences were subsequently located by two-sample Student’s
t-tests for parametric data, or, in the presence of out-liars,
by nonparametric Kruskal-Wallis tests. For all analyses, testing
proceeded only when significant responses, differences and/or
interactions were indicated. The P-value was for all tests and
each step adjusted according to Bonferroni, except for the
catecholamine data, where P ≤ 0.05 was considered significant.
The number of rats included in each group, i.e., 6–8 rats, was
based on sample power calculations using previous data from
similar or related experiments.
RESULTS
The Influence of α2AR and AT1R on the
Plasma Catecholamine Concentrations
(Table 1)
Norepinephrine
The tyramine-induced norepinephrine overflow to plasma in
female control rats of both strains was not different from that in
male rats (P = NS). The concentration of norepinephrine was
greater in SHR than in WKY in both genders (P = 0.002). In
females of both strains, the non-selective α2AR agonist clonidine
reduced the tyramine-induced norepinephrine overflow to
plasma (P ≤ 0.022), whereas the antagonist L-659,066 increased
norepinephrine overflow (P = 0.044 and P = 0.007 in WKY
and SHR, respectively). The α2(non−A)AR agonist ST-91 and the
AT1R antagonist losartan had alone no effect on the tyramine-
induced overflow in either strain (P =NS). After L-659,066+ST-
91+tyramine, norepinephrine overflow was not different from
that after L-659,066+tyramine in female WKY (P = NS), but
was higher in SHR (P = 0.015). Overflow to plasma was
higher in female WKY pre-treated with losartan+L-659,066
than that in the controls (P = 0.039) but not different from
that after losartan alone (P = NS) and slightly less than that
after L-659,066 alone (P = 0.003). In female SHR, losartan
potentiated the augmenting effect of L-659,066 on tyramine-
induced norepinephrine overflow (P ≤ 0.006 compared to the
controls or the losartan/L-659,066-only groups). Please see (Berg,
2013; Berg and Jensen, 2013) for similar studies on male rats.
Epinephrine
Strain- and gender-related differences were not observed in the
plasma epinephrine concentration. Clonidine, ST-91 and losartan
had no effect on the plasma epinephrine concentration in female
rats of either strain (P = NS), except for a small increase
after losartan in WKY (P = 0.037). The antagonist L-659,066
increased the secretion of epinephrine in both strains (P≤ 0.021).
The plasma epinephrine concentration after ST-91/losartan+L-
659,066 was not different from that after L-659,066 alone inWKY,
but was higher than that after L-659,066-only in SHR (P≤ 0.036).
Cardiovascular Baselines and Response to
Pre-Treatment
Strain-, Gender- and Age-Related Differences in BP
and HR
When BP and HR were recorded in the anesthetized rats after
femoral artery catheterization but before the rats were connected
to the respirator (Table 2), the 12–14 weeks-old male SHR were
clearly hypertensive whereas the female SHR of the same age
were not. Also baseline HR was higher in these SHR than in
WKY in the males (P < 0.001) but not in the females (P =
NS). Thus, HR was higher in male than in female SHR (P <
0.001), whereas a gender-dependant difference was not present
in WKY (P = NS). However, when the rats were about 1 year
old, both male and female SHR were hypertensive (P ≤ 0.007)
and HR was higher than that in WKY in both genders (P =
0.001; Table 2). Age-related differences in BP and HR were
not observed in WKY. These observations demonstrated that
the female SHR were in a pre-hypertensive stage at the age of
12–14 weeks.
TABLE 1 | The plasma concentration of norepinephrine and epinephrine at the end of the tyramine-infusion period in 12–14 weeks old rats.
WKY SHR
Norepinephrine (nM) Epinephrine (nM) Norepinephrine (nM) Epinephrine (nM)
MALE RATS:
PBS+tyramine 21.0 ± 1.2 4.3 ± 1.3 27.3 ± 2.0* 6.7 ± 1.1
FEMALE RATS:
PBS+tyramine 23.4 ± 1.6 1.5 ± 0.7 32.7 ± 1.9* 4.1 ± 2.2
Clonidine+tyramine 18.0 ± 0.5† 1.2 ± 0.3 27.1 ± 0.8*† 1.8 ± 0.5
L-659,066+tyramine 34.4 ± 4.2† 15.3 ± 5.7† 43.9 ± 2.8† 11.2 ± 3.1†
PBS+ST-91+tyramine 25.7 ± 2.1 3.6 ± 1.5 36.5 ± 3.8* 10.5 ± 5.4
L-659,066+ST-91+tyramine 36.1 ± 3.4†‡ 15.2 ± 4.3†‡ 53.6 ± 2.9*†‡§ 21.3 ± 2.7*†‡§
Losartan+PBS 25.3 ± 0.7 6.4 ± 1.7† 27.1 ± 1.9 3.7 ± 1.3
Losartan+L-659,066+tyramine 30.3 ± 2.4†§ 10.2 ± 2.5† 67.7 ± 9.0*†‡§ 27.0 ± 5.3†‡§
Differences were detected as indicated between corresponding SHR and WKY groups (* after SHR values), between the female PBS+tyramine controls and corresponding experimental
groups (
†
), between corresponding groups pre-treated with ST-91/losartan alone and ST-91/losartan+L-659,066 (
‡
), and between the groups pre-treated with ST-91/losartan+L-
659,066 and L-659,066 alone (§). Gender-dependant differences within each strain in rats treated with PBS+tyramine were not detected. In male time-controls, infused with PBS
instead of tyramine, the plasma norepinephrine and epinephrine concentrations were 0.7 ± 0.2 and 6.9 ± 1.2 nM, respectively in WKY, and 1.3 ± 0.2 and 10.9 ± 1.9 nM in SHR (Berg,
2014). *,
†
,
‡
P ≤ 0.05.
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TABLE 2 | Resting BP and HR in young and old, male and female WKY and SHR.
WKY SHR
SBPmm Hg DBPmm Hg MBPmm Hg HR bpm SBPmm Hg DBPmm Hg MBPmm Hg HR bpm
12–14 WEEKS OLD RATS
Male 103 ± 8 73 ± 6 83 ± 6 312 ± 15 183 ± 18* 146 ± 12* 157 ± 15* 421 ± 9*
Female 87 ± 7 61 ± 7 70 ± 7 317 ± 13 108 ± 8† 75 ± 8† 86 ± 8† 349 ± 10†
45–54 WEEKS OLD RATS
Male 109 ± 4 76 ± 8 87 ± 7 253 ± 20 175 ± 12* 140 ± 10* 152 ± 10* 367 ± 14*‡
Female 96 ± 9 68 ± 7 78 ± 8 285 ± 5 170 ± 14*‡ 129 ± 11*‡ 143 ± 12*‡ 376 ± 16*
BP and HR baselines were recorded through the femoral artery before the rats were connected to the respirator and before thoracotomy. Comparisons were made between WKY and
SHR within each gender (* after SHR values), between male and female rats within each strain (
†
after female values) and between corresponding young and older rats (
‡
after older
rats). MBP in both strains and HR in WKY were reduced by the anesthesia, and were in chronically catheterized, awake, 12-14 weeks-old rats measured to be 113 ± 8 and 169 ±
4mm Hg, and 399 ± 22 and 407 ± 12 bpm, in male WKY and SHR, respectively. SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean arterial blood pressure; HR,
heart rate. *,
†
P ≤ 0.009.
Impact of Artificial Ventilation on BP
As previously discussed for male rats (Berg and Jensen, 2013),
SHR were more sensitive to the reduced venous return to the
right heart during positive-PEEP-ventilation than WKY also in
female rats. Thus, after the 12–14 weeks-old rats were connected
to the respirator and surgery completed, i.e., prior to pre-
treatment, SBP/DBP/MBP were reduced in male SHR and SBP
in female SHR (P ≤ 0.008), but not in male or female WKY
(P = NS; Table 3). The changes in HR were not statistically
significant.
Strain- and Gender-Related Differences in CO and
TPR
CO and TPR were monitored only after the 12–14 weeks-old rats
were connected to the computer, and the surgery was completed.
CO baseline was higher in male than in female rats of both strains
(Table 3), but when adjusted for the gender-dependant difference
in body weight, the cardiac index (CI = CO/kg body weight)
was higher in females than in males in WKY (142 ± 5 and
110± 6ml/min/kg, respectively, P = 0.001), but not different in
SHR (90 ± 5 and 78 ± 6 ml/min/kg, P = NS). A lower CI was
therefore observed in SHR compared to WKY in both genders
(P ≤ 0.005). At this time, baseline TPR was higher in SHR than
inWKY in the males (P= 0.009), but not different in the females
(P = NS; Table 3).
The Effect of Pre-Treatment
Group differences in baseline MBP, HR, CO and TPR prior to
pre-treatment within each strain of female rats were not observed
(P = NS). Baselines after pre-treatment and the effect of pre-
treatment in the 12–14 weeks-old rats are shown in Table 3.
Clonidine induced an immediate and transient rise in BP and
TPR, which subsequently declined to below baseline in both
strains (P ≤ 0.009 after 15min; Figure 3). Also ST-91 (not
shown) induced a transient and highly variable (51–825%) rise
in TPR in the female rats of both strains, and a significant
reduction was not seen after prior administration of L-659,066.
Large variations were observed in the TPR-response to ST-
91 also after 15min, and an effect of L-659,066 could not
be deciphered (Table 3). Both clonidine (Figure 3) and ST-91
induced a transient bradycardia in WKY, whereas clonidine
precipitated a sustained reduction in HR in SHR (P = 0.004 for
WKY vs. SHR after 15min). L-659,066 eliminated the immediate
HR-response to ST-91 in WKY (P = 0.025 compared to the ST-
91-only group). L-659,066 had no effect on the cardiovascular
baselines, whereas losartan reduced MBP and TPR in both
strains and in SHR also HR (P ≤ 0.007; Table 3). The effect
of losartan+L-659,066 was largely the same as that of losartan
alone, although the differences were not always statistically
significant.
The Influence of α2AR- and AT1R on the
Cardiovascular Response to Tyramine in
12–14 Weeks-Old Rats
The Cardiovascular Response to Tyramine in Female
and Male Control Rats
Like in male rats, tyramine induced a rise in TPR also in female
rats (Figures 4, 5) and a sustained increase in MBP, CO (not
shown) and HR (Figure 6). As in the male, the TPR-response
in female rats was transient in WKY, but sustained in SHR (P =
0.004 for a strain-related difference at 15min; Figure 4). The TPR
peak-response was less in females than in males in WKY (P <
0.001) but not different in SHR (P = NS; Figures 4, 5). Also the
parallel MBP-peak response to tyramine was slightly less in the
females than in the males inWKY (∆MBP at 5min= 47± 3 and
60± 3mmHg, respectively, P= 0.006), but higher in the females
in SHR (67 ± 6 and 51 ± 7mm Hg, P = 0.003). The MBP peak-
response was higher in SHR than in WKY in the females only
(P = 0.013). However, the rise in CO at the end of the 15min-
tyramine-infusion period, expressed in percentage change to
correct for differences in body weight and baseline CI, was about
half in male SHR compared to that in females (1CO = 27 ± 5
and 56 ± 7%, respectively, P = 0.008), but not different in WKY
(64± 8 and 60 ± 1% in male and females, respectively, P = NS).
In the males, the tyramine-induced tachycardia in SHR was
about half of that in WKY (P = 0.001), whereas a strain-related
difference was not observed in the females (P = NS; Figure 6).
Frontiers in Neuroscience | www.frontiersin.org 5 March 2016 | Volume 10 | Article 130
Berg Hypertension Control in Female Rats
T
A
B
L
E
3
|
C
a
rd
io
v
a
s
c
u
la
r
b
a
s
e
li
n
e
s
in
th
e
1
2
–1
4
w
e
e
k
s
o
ld
ra
ts
a
ft
e
r
p
re
-t
re
a
tm
e
n
t,
i.
e
.,
p
ri
o
r
to
ty
ra
m
in
e
,
w
it
h
th
e
re
s
p
o
n
s
e
to
p
re
-t
re
a
tm
e
n
t
s
h
o
w
n
b
e
lo
w
in
p
a
re
n
th
e
s
is
.
P
re
-t
re
a
tm
e
n
t
W
K
Y
S
H
R
M
B
P
m
m
H
g
H
R
b
p
m
C
O
m
l/
m
in
T
P
R
m
m
H
g
/m
l/
m
in
M
B
P
m
m
H
g
H
R
b
p
m
C
O
m
l/
m
in
T
P
R
m
m
H
g
/m
l/
m
in
M
a
le
:
P
B
S
6
1
±
4
(−
8
±
3
)
3
3
0
±
1
4
(-
1
2
±
6
)
3
2
±
2
(0
±
1
)
1
.9
±
0
.1
(−
0
.3
±
0
.1
)
9
2
±
7
*
(−
6
±
3
)
3
9
9
±
1
0
*
(−
4
±
4
)
2
2
±
2
*
(−
1
±
1
)
4
.3
±
0
.3
*
(−
0
.2
±
0
.2
)
F
e
m
a
le
:
P
B
S
7
5
±
5
(1
±
3
)
3
4
4
±
8
(−
1
±
5
)
2
6
±
0
†
(1
±
1
)
2
.9
±
0
.2
†
(−
0
.1
±
0
.1
)
5
6
±
3
*†
(−
1
0
±
3
)
3
6
6
±
1
1
(−
2
5
±
3
)
1
6
±
1
*
(−
1
±
0
)
3
.6
±
0
.1
*
(−
0
.5
±
0
.2
)
C
lo
n
id
in
e
6
4
±
5
(−
2
±
3
)
3
1
4
±
1
6
(−
2
9
±
8
)
2
6
±
2
(6
±
1
)‡
2
.6
±
0
.3
(−
0
.8
±
0
.2
)‡
5
5
±
3
(−
1
8
±
8
)
3
1
3
±
1
4
(−
8
1
±
1
1
)‡
1
6
±
2
(3
±
1
)
3
.6
±
0
.3
(−
2
.0
±
0
.3
)‡
L
-6
5
9
,0
6
6
5
4
±
6
(−
8
±
3
)
3
5
6
±
8
(−
4
±
5
)
2
6
±
3
(0
±
1
)
2
.3
±
0
.3
(−
0
.2
±
0
.1
)
5
2
±
4
(−
2
5
±
4
)
3
5
0
±
1
1
(−
4
0
±
8
)
1
2
±
1
(−
4
±
1
)
5
.3
±
1
.5
(0
.2
±
0
.9
)
P
B
S
+
S
T-
9
1
7
6
±
9
(1
2
±
1
0
)
3
5
2
±
1
5
(−
1
1
±
4
)
2
9
±
2
(3
±
1
)
2
.8
±
0
.4
(0
.2
±
0
.3
)
9
7
±
1
5
(2
8
±
3
)
3
4
8
±
1
4
(−
6
4
±
1
8
)
1
6
±
3
(0
±
1
)
6
.7
±
1
.4
(2
.0
±
1
.0
)
L
-6
5
9
,0
6
6
+
S
T-
9
1
5
4
±
2
(−
1
4
±
6
)
3
4
9
±
1
1
(−
1
7
±
1
8
)
3
0
±
2
(5
±
2
)
1
.8
±
0
.1
‡
(−
0
.9
±
0
.3
)‡
8
2
±
1
2
(4
±
3
)
3
6
2
±
6
(−
4
1
±
1
1
)
2
0
±
6
(−
1
±
1
)
5
.6
±
1
.3
(1
.1
±
0
.8
)
L
o
sa
rt
a
n
4
0
±
2
(−
2
9
±
4
)‡
3
4
5
±
1
1
(−
2
5
±
7
)
2
4
±
1
(−
5
±
2
)‡
1
.7
±
0
.1
‡
(−
0
.7
±
0
.2
)
4
8
±
3
‡
(−
3
8
±
6
)‡
3
2
5
±
7
(−
6
2
±
4
)‡
1
3
±
1
(−
3
±
0
)‡
3
.8
±
0
.2
(−
1
.7
±
0
.3
)‡
L
o
sa
rt
a
n
+
L
-6
5
9
,0
6
6
3
7
±
2
(−
2
9
±
4
)‡
3
2
7
±
1
4
(−
2
5
±
1
0
)
2
6
±
1
(0
±
1
)
1
.4
±
0
.1
(−
1
.1
±
0
.1
)‡
3
7
±
2
‡
(−
4
1
±
8
)‡
3
4
1
±
7
(−
4
8
±
1
1
)‡
1
2
±
1
(−
3
±
1
)
3
.3
±
0
.2
(−
2
.2
±
0
.7
)‡
C
o
m
p
a
ri
s
o
n
s
w
e
re
m
a
d
e
b
e
tw
e
e
n
th
e
W
K
Y
a
n
d
S
H
R
c
o
n
tr
o
ls
w
it
h
in
e
a
c
h
g
e
n
d
e
r
(*
a
ft
e
r
S
H
R
va
lu
e
s
),
b
e
tw
e
e
n
fe
m
a
le
a
n
d
m
a
le
P
B
S
-c
o
n
tr
o
ls
w
it
h
in
e
a
c
h
s
tr
a
in
(†
a
ft
e
r
fe
m
a
le
va
lu
e
s
),
a
n
d
b
e
tw
e
e
n
th
e
fe
m
a
le
P
B
S
-c
o
n
tr
o
ls
a
n
d
th
e
e
xp
e
ri
m
e
n
ta
l
g
ro
u
p
s
(‡
).
S
ig
n
ifi
c
a
n
t
d
iff
e
re
n
c
e
s
w
e
re
n
o
t
d
e
te
c
te
d
b
e
tw
e
e
n
th
e
g
ro
u
p
s
p
re
-t
re
a
te
d
w
it
h
P
B
S
+
S
T-
9
1
(α
2
C
A
R
-s
u
b
ty
p
e
-s
e
le
c
ti
ve
a
g
o
n
is
t)
a
n
d
L
-6
5
9
,0
6
6
(p
e
ri
p
h
e
ra
l,
n
o
n
s
e
le
c
ti
ve
α
2
A
R
a
n
ta
g
o
n
is
t)
+
S
T-
9
1
,
o
r
b
e
tw
e
e
n
th
e
g
ro
u
p
s
p
re
-t
re
a
te
d
w
it
h
th
e
a
n
g
io
te
n
s
in
A
T
1
re
c
e
p
to
r
a
n
ta
g
o
n
is
t
lo
s
a
rt
a
n
a
lo
n
e
a
n
d
lo
s
a
rt
a
n
+
L
-6
5
9
,0
6
6
(P
<
0
.0
2
5
).
M
B
P,
m
e
a
n
a
rt
e
ri
a
lb
lo
o
d
p
re
s
s
u
re
;
H
R
,
h
e
a
rt
ra
te
;
C
O
,
c
a
rd
ia
c
o
u
tp
u
t;
T
P
R
,
to
ta
lp
e
ri
p
h
e
ra
lv
a
s
c
u
la
r
re
s
is
ta
n
c
e
.
*,
†
P
≤
0
.0
1
2
5
,
‡
P
≤
0
.0
0
8
3
.
FIGURE 3 | The change in total peripheral vascular resistance (TPR)
and heart rate (HR) in response to the non-selective α2AR agonist
clonidine in female WKY and SHR (12–14 weeks-old rats). Clonidine
penetrates the blood-brain barrier. TPR prior to clonidine was 2.6 ± 0.3 and
3.6 ± 0.3mm Hg/ml/min in WKY and SHR, respectively (P = 0.02). *Within
symbols; significant responses, and * in brackets; significant differences
between WKY and SHR, detected at peak/nadir response or after 15min, as
indicated. *, *P < 0.025 after curve evaluation.
The Effect of α2AR Agonist and Antagonist on the
TPR-Response to Tyramine in Female Rats
Pre-treatment with clonidine or ST-91 had no effect on
the TPR-response to tyramine in female WKY (P = NS),
whereas L-659,066 changed the vasoconstriction to a vasodilatory
response (Figures 4, 5). Additional pre-treatment with ST-91
eliminated the late part of this vasodilatation. In female SHR,
clonidine reduced, but did not eliminate, the vasoconstrictory
TPR-response to tyramine (Figures 4, 5). Also ST-91 reduced
the TPR-peak-response and in addition eliminated the late
vasoconstriction induced by tyramine in this strain. Furthermore,
L-659,066, alone or combined with ST-91, almost totally
eliminated the vasoconstriction throughout the infusion-period
in the female SHR, although did not induce vasodilatation as in
WKY (Figures 4, 5).
The Interaction between AT1R and α2AR in the
TPR-Response to Tyramine in Female Rats
Losartan alone had no significant effect on the TPR-response
to tyramine in either strain in female rats (Figure 7). In
WKY, losartan eliminated the L-659,066-dependant vasodilatory
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FIGURE 4 | The change in total peripheral vascular resistance (TPR) in
response to tyramine-induced norepinephrine release in 12–14
weeks-old, male and female WKY and SHR control rats, and in female
rats pre-treated with α2AR agonist and/or antagonist as indicated by
the symbol legends. Baselines prior to tyramine are shown in Table 3.
Significant responses (* within symbol) and differences between corresponding
male and female control groups, between the female control and experimental
groups, and between corresponding PBS+ST-91+tyramine and
L-659,066+ST-91+tyramine groups were located at peak response, or after
4min when a peak was not present (*, brackets left of curves). Similar analyses
were done after 15min (*, brackets right of curves). Significant responses and
group differences other than those indicated were not found. The
TPR-peak-response is shown as a bar graph in Figure 5. *, *P ≤ 0.025 after
curve evaluations.
response to tyramine. In SHR, the TPR-response to tyramine was
eliminated after pre-treatment with losartan+L-659,066, as after
L-659,066 alone (Figure 7).
The Influence of α2AR and AT1R on the
HR-Response to Tyramine in Female Rats
None of the pre-treatments influenced the tyramine-induced
tachycardia in the female WKY (Figure 6). In the female SHR,
there was a slight increase after clonidine and a slight reduction
after L-659,066+ST-91 and losartan+L-659,066. L-659,066 and
losartan alone did not influence the tachycardia (Figure 6).
DISCUSSION
The main findings in the present study were that α2AR
inhibition of peripheral norepinephrine and epinephrine release
and control of vascular tension during tyramine-stimulated
norepinephrine release was functional in the anesthetized, 12–14
weeks-old, female SHR, unlike that previously observed in age-
matched male SHR (Berg and Jensen, 2013). Although the female
FIGURE 5 | A bar graph demonstrating the initial change in total
peripheral vascular resistance (TPR) in response to tyramine in the
same experiments as shown in Figure 4. Group identity is indicated by the
symbol legends, i.e., male controls (PBS+tyramine) and female controls and
experimental groups pre-treated with α2AR agonist or antagonist. Significant
responses (* within column) and differences between corresponding male and
female control groups, between the female control and experimental groups,
and between corresponding groups given PBS+ST-91+tyramine and
L-659,066+ST-91+tyramine were located at peak response, or after 4min
when a peak was not present (*, brackets left of curves). Statistical analyses
were performed as indicated in Figure 4 legend. *, *P ≤ 0.025 after curve
evaluations.
SHR did develop high BP later in life, at this early age, the female
SHRwere pre-hypertensive with a resting BP andHR close to that
in the female WKY and much lower than that in the male SHR.
The Role of α2AR in Control of
Catecholamine Release in 12–14
Weeks-Old Rats
The ability of presynaptic α2AR to limit peripheral
norepinephrine release in female rats was demonstrated by
the fact that the non-selective α2AR-agonist clonidine reduced
tyramine-induced norepinephrine overflow to plasma in both
strains. In the males, clonidine reduced overflow only in SHR,
indicating that α2AR were fully activated in the male WKY
but could be further activated in male SHR (Berg and Jensen,
2013). Although clonidine easily crosses the blood-brain barrier,
tyramine does not. The differences in norepinephrine overflow
after clonidine were therefore likely to depend on activation
of presynaptic α2AR in peripheral sympathetic nerves. The
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FIGURE 6 | The heart rate (HR)-response to tyramine-induced
norepinephrine release in 12–14 weeks-old, male and female WKY and
SHR control rats, and in female rats pre-treated with α2AR agonist
and/or antagonist as indicated by the symbol legends. Baselines prior to
tyramine are shown in Table 3. The change in HR after 15min was statistically
significant in all groups (not indicated). Differences between the corresponding
male and female control groups, and between the corresponding female
control and experimental groups were detected as indicated at 15min
(*, brackets right of curves). *P ≤ 0.05 after curve evaluations.
peripherally-acting α2(noneA)AR agonist ST-91 did not lower
tyramine-induced norepinephrine overflow in female rats,
suggesting that auto-inhibition of release depended primarily on
the α2AAR subtype, similar to that previously observed in male
rats (Starke, 2001; Brede et al., 2004; Berg, 2013).
However, the adrenal α2AR in females seemed almost fully
activated in both strains since the clonidine-induced reduction
in the plasma epinephrine concentration was not statistically
significant in either strain. Clonidine reduced the plasma
epinephrine concentration in both strains in the males (Berg and
Jensen, 2013). Adrenal epinephrine secretion may therefore be
better controlled by α2AR in female than in male SHR.
An actual contribution of the α2AR in inhibition of release was
confirmed by the increased plasma catecholamine concentrations
after pre-treatment with the non-selective α2AR-antagonist L-
659,066. Different from that in the males, where L-649,066
increased tyramine-induced norepinephrine overflow in WKY
only (Berg and Jensen, 2013), L-659,066 increased the plasma
norepinephrine concentration in both strains in female rats. Also
the α2AR-mediated auto-inhibition of epinephrine secretion was
functional in both strains in female rats, demonstrated by an
FIGURE 7 | The change in total peripheral vascular resistance (TPR) in
response to tyramine in 12–14 weeks-old, female WKY and SHR
pre-treated with the AT1R antagonist losartan, alone or combined with
L-659,066. Baselines prior to tyramine are shown in Table 3. Significant
responses (* within symbol) and group differences between the control and
experimental groups, and between the losartan+L-659,066+tyramine and the
L-659,066+tyramine or losartan+tyramine groups were detected at peak
response, or after 4min when a peak was not present (*, brackets left of
curves). Similar analyses were performed for the response after 15min (*,
brackets right of curves) as indicated. *, *P ≤ 0.025 after curve evaluations.
increased plasma epinephrine concentration after pre-treatment
with L-659,066. A similar increase was seen only in WKY and
not in SHR in male rats (Berg and Jensen, 2013). Thus, in the
female, pre-hypertensive SHR, α2AR-mediated auto-inhibition
of norepinephrine and epinephrine release was clearly functional,
unlike that in the male SHR.
The failing α2AAR-mediated inhibition of catecholamine
release in male SHR was restored by augmented α2CAR
signaling, either by directly stimulating the α2CAR with
agonist or by inhibiting the angiotensin AT1R (Berg, 2013),
which interferes with α2CAR down-stream signaling (Cox
et al., 2000; Trendelenburg et al., 2003b; Figure 1). Although
α2AAR-mediated auto-inhibition was functional in female SHR,
enhanced α2CAR signaling potentiated their effect also in this
gender, as indicated by the elevated plasma norepinephrine and
epinephrine concentrations observed after pre-treatment with
ST-91+L-659,066 or losartan+L-659,066 compared to L-659,066
alone. A similar increase was not seen in the female WKY,
or, previously, in male WKY (Berg, 2013). The reason for the
potentiating effect of α2CAR on α2AAR auto-inhibition was
not clear, but may be due to that α2AR were likely to form
heterodimers (Figure 1), and the α2Aα2CAR heterodimer was
more stable against G-protein coupled receptor kinase 2 (GRK2)
desensitization than the α2Aα2Aor α2Cα2C homodimers (Small
et al., 2006). Another possible explanation in this in vivo model
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was that α2CAR may hamper renal renin release (Michel and
Rump, 1996), and, in that manner, may lower AT1R-mediated
counter-action of the α2A/2CAR-mediated inhibition of release.
The Role of α2AR in Control of Vascular
Tension
One may assume that the VSMC AR are activated in
a physiological situation primarily by sympathetic nerve
transmitter release, whereas the endothelial cell receptors are
influenced primarily by components present in the circulation.
However, tyramine stimulates a massive and sustained release of
norepinephrine. In this artificial situation, where norepinephrine
NET re-uptake is prevented by the tyramine-stimulated release
through the same transporter, the plasma concentration
of norepinephrine is greatly increased, and the released
norepinephrine may influence not only the VSMC receptors
but also endothelial receptors. It is not possible to clearly
differentiate between VSMC and endothelial activation in this
in vivo experimental model, but vasodilatory components
attributable to norepinephrine-activated endothelial receptors
were not detected. However, one may assume that the tyramine-
stimulated release of norepinephrine was much greater than
that needed for VSMC activation. The impact of drugs on
the tyramine-induced TPR-response was therefore likely to
reflect a direct effect on the VSMC receptors rather than
on the presynaptic receptors with subsequent differences in
norepinephrine release. This conclusion was supported by
the inverse relationship between plasma catecholamine levels
and the TPR-response to tyramine, for instance in rats pre-
treated with L-659,066. Tyramine, with an action restricted to
peripheral, sympathetic nerve endings, therefore allowed an
investigation of presynaptic control of norepinephrine release
and, independently, the VSMC-response to the endogenously
released norepinephrine.
In the 12–14 weeks-old female rats, clonidine and ST-91
induced a transient rise in TPR, like previously observed in
male rats of the same age. In the males, the rise in TPR
was reduced by L-659,066 (Berg et al., 2012), compatible
with studies on genetically modified mice, where the initial
clonidine-induced vasoconstriction was due to activation of
VSMC α2BAR (Link et al., 1996). The vasoconstrictory TPR-
response to clonidine was less in female SHR than in WKY,
most likely due to a simultaneous clonidine-induced reduction
in central sympathetic output in SHR. This conclusion was
deduced from observations made in male rats, where clonidine
induced a transient, L-659,066-sensitive reduction in HR in
WKY, but a sustained, L-659,066-insensitive bradycardia and
late vasodilatory TPR-response in SHR (Berg et al., 2012). A
clonidine-induced, transient bradycardia was observed also in
female WKY and a sustained bradycardia and late vasodilatation
in female SHR, suggesting an elevated central sympathetic
cardiovascular control in SHR also in this gender.
Also the α2CAR may be involved in the vasoconstrictory
response to clonidine and ST-91, since an L-659,066-sensitive
rise in TPR was seen in male rats also in response to an α2C-
selective agonist, i.e., m-nitrobiphenyline (Berg, 2013), which in
addition contained α2A+BAR antagonistic properties (Crassous
et al., 2007). Although VSMC α2CAR did not contribute to BP-
control in genetically modified mice (MacDonald et al., 1997),
agonist-stimulated α2CAR-mediated vasoconstriction has been
demonstrated in veins and arterioles (Chotani et al., 2004;
Görnemann et al., 2007; Corboz et al., 2011). However, the initial
rise in TPR in response to ST-91 was highly variable in the female
rats, and the effect of L-659,066 on this response was therefore
inconclusive. A similar variation was not observed in male rats
(Berg, 2013). It may therefore be suggested that differences
in the oestrous cycle and oestrogen-induced mobilization of
α2CAR to VSMC surface, as demonstrated in human, cutaneous,
arteriolar VSMC (Eid et al., 2007), caused differences in α2CAR-
mediated vasoconstriction when stimulated with agonist. The
VSMC α2CAR has been shown to be mobilized to the cell surface
also by cold, and in that manner contribute to cold-induced
vasoconstriction (Chotani et al., 2000). A possible influence of the
oestrous cycle may be restricted to the VSMC since ST-91 alone
had no effect on the tyramine-induced catecholamine overflow to
plasma.
As in male WKY, the α2AR agonists clonidine and ST-91
had no effect on the TPR-response to the tyramine-induced
norepinephrine release in female WKY. However, clonidine
reduced the TPR-response in female SHR, but not in the
male SHR (Berg and Jensen, 2013). The mechanism underlying
the effect of clonidine in female SHR was not clear, but
may result from stimulation of endothelial α2AR-mediated
vasodilatation, as observed in male SHR under other conditions
(Shafaroudi et al., 2005; Berg and Jensen, 2011). However,
unlike that in the male SHR, where L-659,066 did not alter
the TPR-response to tyramine (Berg and Jensen, 2013), L-
659,066 eliminated the TPR-response to tyramine in female
SHR. L-659,066 eliminated the TPR-response also in male
WKY and even reversed the response to vasodilatation in the
female WKY. Moreover, ST-91, which enhanced the effect of
L-659,066 in male SHR, had no potentiating effect in female
SHR. Thus, although the TPR-response to tyramine was higher
and more sustained in female SHR than in female WKY,
α2AR control of vascular tension was clearly more functional
than in the male SHR, although not as effective as in the
female WKY.
Unlike that in male WKY (Berg, 2013; Berg and Jensen,
2013), losartan abolished the L-659,066-dependent vasodilatory
response to tyramine in the female WKY. The reason for
this observation was not clear, but a similar effect was seen
for the L-659,066-dependent increase in norepinephrine
overflow, which was slightly less when combined with
losartan. Although losartan restored the hampering effect
of L-659,066 on tyramine-induced vasoconstriction in
male SHR (Berg, 2013; Berg and Jensen, 2013), it had no
additional effect on the inhibitory effect of L-659,066 on
this response in female SHR. It therefore appeared that
when the α2AR control of vascular tension was functional
as in the female, AT1R activity had less potentiating
effect on norepinephrine induced vasoconstriction, even
though losartan clearly lowered TPR baseline also in the
female SHR.
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CONCLUSIONS
These studies show that α2AR-mediated control of catecholamine
release and vascular tension is functional in female, 12–14 weeks-
old SHR, unlike that previously observed in male SHR of the
same age. Functional α2AR-mediated control of catecholamine
release may represent an important mechanism in protecting
females against hypertension and delaying the development of
disease in this gender.
FUNDING
The Norwegian Council on Cardiovascular Diseases and Anders
Jahres’ Fond.
AUTHOR CONTRIBUTIONS
The author confirms being the sole contributor of this work and
approved it for publication.
REFERENCES
Berg, T. (2002). Analysis of the pressor response to the K+ channel inhibitor
4-aminopyridine. Eur. J. Pharmacol. 452, 325–337. doi: 10.1016/S0014-
2999(02)02306-3
Berg, T. (2013). Angiotensin AT1 - alpha2C-adrenoceptor interaction disturbs
alpha2A-auto-inhibition of catecholamine release in hypertensive rats. Front.
Neurol. 4:70. doi: 10.3389/fneur.2013.00070
Berg, T. (2014). beta3-adrenoceptors inhibit stimulated norepinephrine
release in spontaneously hypertensive rats. Front. Physiol. 5:499. doi:
10.3389/fphys.2014.00499
Berg, T., and Jensen, J. (2011). Simultaneous parasympathetic and sympathetic
activation reveals altered autonomic control of heart rate, vascular tension, and
epinephrine release in anesthetized hypertensive rats. Front. Neurol. 2:71. doi:
10.3389/fneur.2011.00071
Berg, T., and Jensen, J. (2013). Tyramine reveals failing alpha2-adrenoceptor
control of catecholamine release and total peripheral vascular resistance in
hypertensive rats. Front. Neurol. 4:19. doi: 10.3389/fneur.2013.00019
Berg, T., Walaas, S. I., Roberg, B. A., Huynh, T. T., and Jensen, J. (2012).
Plasma norepinephrine in hypertensive rats reflects alpha(2)-adrenoceptor
release control only when re-uptake is inhibited. Front. Neurol. 3:160. doi:
10.3389/fneur.2012.00160
Brede, M., Philipp, M., Knaus, A., Muthig, V., and Hein, L. (2004). alpha2-
adrenergic receptor subtypes - novel functions uncovered in gene-targeted
mouse models. Biol. Cell 96, 343–348. doi: 10.1016/j.biolcel.2004.03.006
Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D., and Flavahan, N. A. (2000).
Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in
cutaneous arteries. Am. J. Physiol. 278, H1075–H1083.
Chotani, M. A., Mitra, S., Su, B. Y., Flavahan, S., Eid, A. H., Clark, K. R.,
et al. (2004). Regulation of alpha(2)-adrenoceptors in human vascular smooth
muscle cells. Am. J. Physiol. 286, H59–H67. doi: 10.1152/ajpheart.00268.2003
Clineschmidt, B. V., Pettibone, D. J., Lotti, V. J., Hucker, H. B., Sweeney, B.
M., Reiss, D. R., et al. (1988). A peripherally acting alpha-2 adrenoceptor
antagonist: L-659,066. J. Pharmacol. Exp. Ther. 245, 32–40.
Corboz, M. R., Rivelli, M. A., McCormick, K. D., Wan, Y., Shah, H., Umland,
S., et al. (2011). Pharmacological characterization of a novel alpha2C-
adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-
benzoxazin-6-yl]-N-ethyl-N’-methylurea (compound A). J. Pharmacol. Exp.
Ther. 337, 256–266. doi: 10.1124/jpet.110.175794
Cox, S. L., Schelb, V., Trendelenburg, A. U., and Starke, K. (2000). Enhancement of
noradrenaline release by angiotensin II and bradykinin inmouse atria: evidence
for cross-talk between G(q/11) protein- and G(i/o) protein-coupled receptors.
Br. J. Pharmacol. 129, 1095–1102. doi: 10.1038/sj.bjp.0703167
Crassous, P. A., Cardinaletti, C., Carrieri, A., Bruni, B., Di, V. M., Gentili,
F., et al. (2007). Alpha2-adrenoreceptors profile modulation. 3.1 (R)-(+)-m-
nitrobiphenyline, a new efficient and alpha2C-subtype selective agonist. J. Med.
Chem. 50, 3964–3968. doi: 10.1021/jm061487a
Du, X. J., Dart, A. M., Riemersma, R. A., and Oliver, M. F. (1991). Sex
difference in presynaptic adrenergic inhibition of norepinephrine release
during normoxia and ischemia in the rat heart. Circ. Res. 68, 827–835. doi:
10.1161/01.RES.68.3.827
Eid, A. H., Maiti, K., Mitra, S., Chotani, M. A., Flavahan, S., Bailey,
S. R., et al. (2007). Estrogen increases smooth muscle expression of
alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries.
Am. J. Physiol. 293, H1955–H1961. doi: 10.1152/ajpheart.00306.2007
Garcia-Villalon, A. L., Buchholz, J. N., Duckles, S. P., and Krause, D. N. (1997).
Noradrenaline content and release in male and female rat tail arteries. J.
Cardiovasc. Pharmacol. 29, 93–96. doi: 10.1097/00005344-199701000-00015
Görnemann, T., von, W. H., Kleuser, B., Villalon, C. M., Centurion, D., Jahnichen,
S., et al. (2007). Characterization of the postjunctional alpha 2C-adrenoceptor
mediating vasoconstriction to UK14304 in porcine pulmonary veins. Br. J.
Pharmacol. 151, 186–194. doi: 10.1038/sj.bjp.0707221
Hein, L., Altman, J. D., and Kobilka, B. K. (1999). Two functionally distinct
alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature
402, 181–184. doi: 10.1038/46040
Lerner, D. J., and Kannel, W. B. (1986). Patterns of coronary heart disease
morbidity and mortality in the sexes: a 26-year follow-up of the Framingham
population. Am. Heart J. 111, 383–390. doi: 10.1016/0002-8703(86)90155-9
Link, R. E., Desai, K., Hein, L., Stevens, M. E., Chruscinski, A., Bernstein, D., et al.
(1996). Cardiovascular regulation in mice lacking alpha2-adrenergic receptor
subtypes b and c. Science 273, 803–805. doi: 10.1126/science.273.5276.803
MacDonald, E., Kobilka, B. K., and Scheinin, M. (1997). Gene targeting–homing in
on alpha 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18, 211–219.
doi: 10.1016/S0165-6147(97)90625-8
Makaritsis, K. P., Johns, C., Gavras, I., Altman, J. D., Handy, D. E., Bresnahan,
M. R., et al. (1999). Sympathoinhibitory function of the alpha(2A)-
adrenergic receptor subtype. Hypertension 34, 403–407. doi: 10.1161/01.HYP.
34.3.403
Maris, M. E., Melchert, R. B., Joseph, J., and Kennedy, R. H. (2005). Gender
differences in blood pressure and heart rate in spontaneously hypertensive
and Wistar-Kyoto rats. Clin. Exp. Pharmacol. Physiol. 32, 35–39. doi:
10.1111/j.1440-1681.2005.04156.x
Michel, M. C., and Rump, L. C. (1996). Alpha-Adrenergic regulation of human
renal function. Fundam. Clin. Pharmacol. 10, 493–503. doi: 10.1111/j.1472-
8206.1996.tb00606.x
Ng, A. V., Callister, R., Johnson, D. G., and Seals, D. R. (1993). Age and
gender influence muscle sympathetic nerve activity at rest in healthy humans.
Hypertension 21, 498–503. doi: 10.1161/01.HYP.21.4.498
Oldendorf, W. H. (1971). Brain uptake of radiolabeled amino acids, amines, and
hexoses after arterial injection. Am. J. Physiol. 221, 1629–1639.
Reckelhoff, J. F., and Fortepiani, L. A. (2004). Novel mechanisms responsible
for postmenopausal hypertension. Hypertension 43, 918–923. doi:
10.1161/01.HYP.0000124670.03674.15
Remie, R., Van Rossum, J. X., Coppes, R. P., and Zaagsma, J. (1992). Dysfunctional
presynaptic alpha 2-adrenoceptors expose facilitatory beta 2-adrenoceptors in
the vasculature of spontaneously hypertensive rats. Eur. J. Pharmacol. 211,
257–261. doi: 10.1016/0014-2999(92)90537-E
Seals, D. R., and Esler, M. D. (2000). Human ageing and the sympathoadrenal
system. J. Physiol. 528, 407–417. doi: 10.1111/j.1469-7793.2000.00407.x
Shafaroudi, M. M., McBride, M., Deighan, C., Wokoma, A., Macmillan, J.,
Daly, C. J., et al. (2005). Two “knockout” mouse models demonstrate
that aortic vasodilatation is mediated via alpha2a-adrenoceptors located
on the endothelium. J. Pharmacol. Exp. Ther. 314, 804–810. doi:
10.1124/jpet.105.085944
Small, K. M., Schwarb, M. R., Glinka, C., Theiss, C. T., Brown, K. M., Seman,
C. A., et al. (2006). Alpha2A- and alpha2C-adrenergic receptors form homo-
Frontiers in Neuroscience | www.frontiersin.org 10 March 2016 | Volume 10 | Article 130
Berg Hypertension Control in Female Rats
and heterodimers: the heterodimeric state impairs agonist-promoted GRK
phosphorylation and beta-arrestin recruitment. Biochemistry 45, 4760–4767.
doi: 10.1021/bi052074z
Starke, K. (2001). Presynaptic autoreceptors in the third decade: focus
on alpha2-adrenoceptors. J. Neurochem. 78, 685–693. doi: 10.1046/j.1471-
4159.2001.00484.x
Takano, Y., Takano, M., and Yaksh, T. L. (1992). The effect of intrathecally
administered imiloxan and WB4101: possible role of alpha 2-adrenoceptor
subtypes in the spinal cord. Eur. J. Pharmacol. 219, 465–468. doi: 10.1016/0014-
2999(92)90490-U
Trendelenburg, A. U., Meyer, A., Klebroff, W., Guimaraes, S., and Starke, K.
(2003b). Crosstalk between presynaptic angiotensin receptors, bradykinin
receptors and alpha 2-autoreceptors in sympathetic neurons: a study in
alpha 2-adrenoceptor-deficient mice. Br. J. Pharmacol. 138, 1389–1402. doi:
10.1038/sj.bjp.0705223
Trendelenburg, A. U., Philipp, M., Meyer, A., Klebroff, W., Hein, L., and Starke,
K. (2003a). All three alpha2-adrenoceptor types serve as autoreceptors in
postganglionic sympathetic neurons. Naunyn Schmiedebergs. Arch. Pharmacol.
368, 504–512. doi: 10.1007/s00210-003-0829-x
Zugck, C., Lossnitzer, D., Backs, J., Kristen, A., Kinscherf, R., and Haass, M. (2003).
Increased cardiac norepinephrine release in spontaneously hypertensive rats:
role of presynaptic alpha-2A adrenoceptors. J. Hypertens. 21, 1363–1369. doi:
10.1097/00004872-200307000-00026
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Berg. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 11 March 2016 | Volume 10 | Article 130
